Guillermo Salinas-Escudero

Hacia una base normativa mexicana en la medición de calidad de vida relacionada con la salud, mediante el Formato Corto 36

Objective. To present the results of the application of the short format 36 instrument (SF-36) in the Mexican states of Sonora and Oaxaca. The levels of quality of life were compared with those from Canada and the United States. Material and Methods. The data were obtained using a survey on health service access, usage, and quality. The SF-36 is composed of 36 questions, which represent eight different domains on the health-related quality of life. These domains are used to estimate the physical and mental components of health. Data analysis was performed to calculate the average scores for each domain for the total sample, by gender and age groups in each state. The regional differences were assessed by the difference of means. Results. The total response was 98.5% of the 4200 selected households. The percent response values were similar between the two states. A total of 5961 subjects older than 25 years of age completed the questionnaire. Males scored higher than females in all domains and in both components. Regardless of sex, the highest variation was observed in adults up to 64 years of age mainly in three domains: overall health, social function, and mental health; in the 65-74 year age group occurred mostly in social function and mental health; and in adults older than 75 years only in mental health. The young adult age group (25 to 44 years) showed variation in a greater number of domains, while women exhibited more variation in the “extreme” age groups, 25 to 34 years and 75 years and older. The mean scores in our sample were higher than Duran-Arenas L, Gallegos-Carrillo K, Salinas-Escudero G, Martinez-Salgado H. Hacia una base normativa mexicana en la medicion de calidad de vida relacionada con la salud, mediante el Formato Corto 36. Salud Publica Mex 2004;46:306-315. El texto completo en ingles de este articulo esta disponible en: http://www.insp.mx/salud/index.html

Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico

OBJECTIVE The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. MATERIAL AND METHODS A decision tree was developed in preterm groups [<29 and 29-32 weeks of gestational age (wGA)], by using epidemiological and cost local data; the effectiveness was obtained with a systematic review. Patients were evaluated according to their life expectancy. Mexican Health System perspective was used. Effectiveness measures employed were LYG and QALYs. The costs are reported in USD 2009. RESULTS ICERs per LYG resulted on values of USD

A Frailty Index from Next-of-Kin Data: A Cross-Sectional Analysis from the Mexican Health and Aging Study

25,029 and USD

Cost-Effectiveness Analysis of Different Testing Strategies that Use Antibody Levels to Detect Chronic Hepatitis C in Blood Donors.

29,637 for <29 wGA and 29-32 wGA respectively, whereas ICERs per QALYs obtained in the model accounted for USD

Economic evaluation of the use of exogenous pulmonary surfactants in preterm newborns in a Mexican population

17,532 and USD

Correction: Calculation of the Average Cost per Case of Dengue Fever in Mexico Using a Micro-Costing Approach

20,760. CONCLUSIONS Palivizumab prophylaxis for preterm newborn patients ≤32 weeks of age resulted in a cost-effective alternative.

La transformación del sistema de salud con base en la atención primaria

Objectives. To construct a frailty index from next-of-kin information of the last year of life of community-dwelling 50 years old or older adults and test its association with health services utilization. Methods. Cross-sectional analysis from next-of-kin data available from the last wave of the Mexican Health and Aging Study (MHAS). Measurements. Along with descriptive statistics, the frailty index (FI) was tested in regression models to assess its association with adverse outcomes previous to death: number of hospitalized days in the previous year and number of visits to a physician in the previous year, in unadjusted and adjusted models. Results. From a total of 2,649 individuals the mean of age was 74.8 (±11.4) and 56.3% (n = 1,183) were women. The mean of the FI was of 0.279 (±SD 0.131, R = 0.0–0.738) and distribution was biased to the right. There was a significant association (p < 0.001) between the FI and number of hospitalized days (β = 45.7, 95% CI 36.1–55.4, p < 0.001) and for the number of visits to a physician (β = 25.93, 95% CI 19.27–32.6, p < 0.001) both models adjusted for age and sex. Conclusion. The FI constructed with next-of-kin data showed similar characteristics to similar indexes of older adults. It was independently associated with health care use.

Direct medical costs of neonatal respiratory distress syndrome in two specialized public hospitals in Mexico

Aim. We conducted a cost-effectiveness analysis of seven hepatitis C virus (HCV) testing strategies in blood donors. Methods. Three of the seven strategies were based on HCV diagnosis and reporting guidelines in Mexico and four were from previous and current recommendations outlined by the CDC. The strategies that were evaluated determine antibody levels according to the signal-to-cut-off (S/CO) ratio and use reflex Immunoblot (IMB) or HCV RNA tests to confirm true positive (TP) cases of chronic HCV infection. Costs were calculated from the perspective of the Mexican Institute of Social Security (IMSS). A decision tree model was developed to estimate the expected number of true positive cases and costs for the base-case scenarios and for the sensitivity analyses. Results. Base-case findings indicate an extended dominance of the CDC-USA2 and CDC-USA4 options by the IMSS Mexico3 and IMSS-Mexico1 alternatives. The probabilistic sensitivity analyses results suggest that for a willingness-to-pay (WTP) range of

Análisis del costo y la efectividad de los esquemas de administración de factores de coagulación para el manejo de niños con hemofilia A en México

0–9,000 USD the IMSS-Mexico1 strategy is the most cost-effective of all strategies (

Análisis del costo y la efectividad de los esquemas de administración de factores de coagulación para el manejo de niños con hemofi lia A en México Cost-effectiveness analysis of prophylaxis vs. "on demand" approach in the management in children with hemophilia A in Mexico

5,000 USD per TP). The IMSS-Mexico3, IMSS-Mexico2, and CDC-USA3 strategies are also cost-effective strategies that cost between